Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Circumferential Pulmonary Vein Ablation (CPVA) Versus Antiarrhythmic Drug Therapy in for Paroxysmal Atrial Fibrillation (AF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-70 years~2. History of symptomatic paroxysmal AF lasting more than 6 months. Paroxysms of AF are intended as recurrent self-terminating episodes lasting less than 7 days and occurring more than 2 times every month.~Exclusion Criteria:~1. Pregnancy~2. NYHA functional class III or IV~3. Left atrial size \> 65 mm~4. Left ventricular (LV) ejection fraction \< 35%~5. Contraindication to anticoagulation with warfarin~6. History of myocardial infarction within six months of the procedure~7. Prior catheter or surgical ablation attempt for AF~8. Inability or unwillingness to provide written informed consent~9. Life expectancy less than 1 year~10. Significant comorbid conditions such as: cancer (not cured), end stage renal disease (creatinine clearance \< 20 mL/h), severe chronic obstructive lung disease, cirrhosis, etc)~11. Anticipated cardiac surgery for congenital, valvular, aortic or coronary heart disease.~12. Presence of left atrial thrombus.~13. Prior antiarrhythmic drug therapy with amiodarone, sotalol and flecainide at optimal doses (target 200 mg, 240 mg, 200 mg daily respectively~14. AF burden \< 2 episodes/month~15. WPW~16. Expected survival \< 1 year~17. Contraindications for antiarrhythmics therapy including flecainide, sotalol or amiodarone not listed above:~    * LV hypertrophy (LV mass index \> 125g/m2)~   * thyroid dysfunction (hyperthyroidism or uncontrolled hypothyroidism or thyroid cancer)~   * liver dysfunction (ALT or AST \>2x the reference values)~   * Interstitial lung disease with DLCO\<70% of predicted or severe asthma.~   * QT interval exceeding 400 msec~   * Symptomatic sinus node or atrioventricular node dysfunction unless a pacemaker had been implanted~   * Evidence of stress-induced myocardial ischemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).